Clinical Trial Update: Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo

View source ↗

Summary

Completed clinical trial evaluating regulatory T cells targeting LRP1/CD91 and peripheral blood mononuclear cells in patients with vitiligo. The study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: VITILIGO | Status: COMPLETED